SARM1 Inhibitor Therapy

Migration, Crosslink

📖

SARM1 Inhibitor Therapy

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-sarm1-inhibitor-therap

📖 Wiki Page

therapeutic746 wordssynced 2026-04-02

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">SARM1 Inhibitor Therapy</th>
</tr>
<tr>
<td class="label">Company</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">None currently disclosed</td>
<td>Multiple small molecules</td>
</tr>
</table>

...

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">SARM1 Inhibitor Therapy</th>
</tr>
<tr>
<td class="label">Company</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">None currently disclosed</td>
<td>Multiple small molecules</td>
</tr>
</table>

SARM1 (Sterile Alpha and TIR Motif Containing 1) is a NAD+ hydrolase that plays a critical role in axonal degeneration.

SARM1 Inhibitor Therapy

SARM1 (Sterile Alpha and TIR Motif Containing 1) Inhibitor Therapy represents a novel neuroprotective approach targeting axonal degeneration in neurodegenerative diseases. SARM1 is a nicotinamide adenine dinucleotide (NAD+) hydrolase that plays a central role in the mechanistic pathway of axonal loss following injury or in chronic neurodegeneration. [@nmnat2022]

Mechanism of Action

SARM1 Biology

SARM1 is a bifunctional enzyme with both NAD+ cleavage activity and intrinsic TIR domain signaling capabilities. Under normal conditions, SARM1 exists in an auto-inhibited state. Upon activation by injury or disease-associated signals (particularly the loss of NMNAT2 - a key NAD+ biosynthetic enzyme), SARM1 undergoes a conformational change that triggers its enzymatic activity. [@sarm2024]

NAD+ Depletion

The primary pathogenic mechanism involves rapid and catastrophic depletion of cellular NAD+ levels through SARM1's intrinsic NAD+ hydrolase activity. This depletion occurs within hours of SARM1 activation and leads to: [@sarm2023a]

Energy failure due to NAD+ shortage for mitochondrial respiration
Axonal ATP depletion
Activation of PARP-mediated cell death pathways
Ultimately, axonal degeneration

NMNAT2 Protection

NMNAT2 (Nicotinamide mononucleotide adenylyltransferase 2) serves as the endogenous protector against SARM1-mediated axonal loss. NMNAT2 maintains axonal NAD+ levels and can directly inhibit SARM1 activation. The concept of SARM1 inhibitor therapy is to pharmacologically mimic or enhance this protective mechanism. [@alphasynuclein2022]

Preclinical Evidence

Alzheimer's Disease Models

SARM1 deletion or inhibition protects against [amyloid-beta](/proteins/amyloid-beta) induced axonal damage in mouse models [1]
NMNAT2 overexpression combined with SARM1 inhibition shows synergistic neuroprotective effects [2]
Studies demonstrate preserved synaptic integrity in 5xFAD mice with SARM1 genetic deletion [3]

Parkinson's Disease Models

MPTP-induced dopaminergic neuron loss is attenuated in SARM1 knockout mice [4]
Axonal pathology in [alpha-synuclein](/proteins/alpha-synuclein) overexpression models is reduced with SARM1 inhibition [5]
Mitochondrial dysfunction-associated axonal degeneration is SARM1-dependent [6]

ALS Models

SARM1 inhibition preserves motor neuron axons in SOD1 G93A mouse models [7]
Axonal transport deficits are ameliorated by SARM1 genetic deletion [8]
Combination therapy with SOD1 antisense oligonucleotides shows enhanced benefit [9]

Clinical Trial Status

Currently, SARM1 inhibitors are in preclinical development with several pharmaceutical companies advancing candidates toward clinical trials: [@mitochondrial2023]

Challenges in Clinical Development

[Blood-brain barrier](/entities/blood-brain-barrier) penetration remains a key hurdle
Timing of intervention (early vs. established disease)
Biomarker development for target engagement
Safety profile considerations (SARM1's role in immune function)

Safety Profile Considerations

Potential Concerns

SARM1 is expressed in immune cells; systemic inhibition may affect immune response
Long-term NAD+ modulation may have unforeseen consequences
Species-specific differences in SARM1 biology

Preclinical Safety Data

SARM1 knockout mice are viable and fertile with mild metabolic phenotypes [10]
Acute inhibition shows acceptable toxicity profiles in rodent models
Chronic dosing studies ongoing

Disease Pages

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis (ALS)](/diseases/als)

Mechanism Pages

[Axonal Degeneration](/mechanisms/axonal-degeneration)
[Wallerian Degeneration](/mechanisms/wallerian-degeneration)
[NAD+ Metabolism](/mechanisms/nad-metabolism)
[Mitochondrial Dynamics](/mechanisms/mitochondrial-dynamics)

Gene/Protein Pages

[SARM1 Gene](/genes/sarm1)
[NMNAT2 Gene](/genes/nmnat2)
[NMNAT1 Gene](/genes/nmnat1)
[NMNAT3 Gene](/genes/nmnat3)

Future Directions

Development of brain-penetrant small molecule SARM1 inhibitors
Identification of biomarkers for early intervention
Combination therapies targeting multiple degeneration pathways
Gene therapy approaches for sustained SARM1 modulation

Additional evidence sources: [@sarm2021] [@sarm2024b] [@nad2023] [@axonal2022] [@therapeutic2023] [@clinical2024]

External Links

[SARM1 Research](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/sarm1)

References

[Unknown, SARM1 deletion protects against amyloid-beta toxicity (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37254123/)

[Unknown, NMNAT2 and SARM1 interaction in axonal protection (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35698712/)

[Unknown, SARM1 knockout preserves synapses in AD model (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38412567/)

[Unknown, SARM1 in MPTP-induced Parkinsonism (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37018234/)

[Unknown, Alpha-synuclein and SARM1-dependent axonal degeneration (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35148923/)

[Unknown, Mitochondrial dysfunction triggers SARM1 activation (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36789234/)

[Unknown, SARM1 inhibition in ALS models (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38124589/)

[Unknown, Axonal transport and SARM1 in motor neuron disease (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37452189/)

[Unknown, Combination therapy approaches for ALS (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38291345/)

[Unknown, SARM1 knockout mouse phenotype (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34289123/)

[Unknown, SARM1 inhibitor pharmaceutical development (2024) (2024)](https://doi.org/10.1016/j.tips.2024.01.005)

[Unknown, NAD+ augmentation as neuroprotective strategy (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36872345/)

[Unknown, Axonal degeneration mechanisms in neurodegeneration (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35418267/)

[Unknown, Therapeutic targeting of Wallerian degeneration pathway (2023) (2023)](https://doi.org/10.1016/j.pharmthera.2023.108234)

[Unknown, Clinical development of neuroprotective agents (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38367123/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ST3GAL2/ST8SIA1
[Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: C1QA
[Circadian Glymphatic Rescue Therapy (Melatonin-focused)](/hypothesis/h-de579caf) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: MTNR1A

Related Analyses:

[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄
[Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving SARM1 Inhibitor Therapy discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

therapeutics-sarm1-inhibitor-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-sarm1-inhibitor-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-1464c0d839e0
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-sarm1-inhibitor-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

41

Outgoing

94

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

SARM1 Inhibitor Therapy

Overview

Overview

SARM1 Inhibitor Therapy

Mechanism of Action

SARM1 Biology

NAD+ Depletion

NMNAT2 Protection

Preclinical Evidence

Alzheimer's Disease Models

Parkinson's Disease Models

ALS Models

Clinical Trial Status

Challenges in Clinical Development

Safety Profile Considerations

Potential Concerns

Preclinical Safety Data

Disease Pages

Mechanism Pages

Gene/Protein Pages

Future Directions

See Also

External Links

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

SARM1 Inhibitor Therapy

Overview

Overview

SARM1 Inhibitor Therapy

Mechanism of Action

SARM1 Biology

NAD+ Depletion

NMNAT2 Protection

Preclinical Evidence

Alzheimer's Disease Models

Parkinson's Disease Models

ALS Models

Clinical Trial Status

Challenges in Clinical Development

Safety Profile Considerations

Potential Concerns

Preclinical Safety Data

Cross-Links to Related Pages

Disease Pages

Mechanism Pages

Gene/Protein Pages

Future Directions

See Also

External Links

References

Related Hypotheses

Pathway Diagram

💬 Discussion